Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lirafugratinib

Phase 2Small molecule

EElevar Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

FGFR2 Gene Fusion/rearrangementRecruiting

FGFR2 Gene Fusion/rearrangementPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

FGFR2 Gene Fusion/rearrangement

NCT07359820

Clinical

Trials by Indication[1]

FGFR2 Gene Fusion/Rearrangement1 trial

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

Recruiting·EElevar Therapeutics·Phase 2·NCT07359820·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lirafugratinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lirafugratinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lirafugratinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Elevar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EElevar Therapeutics

Related News